Synthesis and preclinical validation of novel P2Y1 receptor ligands as a potent anti-prostate cancer agent.
Purinergic receptor is a potential drug target for neuropathic pain, Alzheimer disease, and prostate cancer. Focusing on the structure-based ligand discovery, docking analysis on the crystal structure of P2Y
Institute for Systems Biology
Le, Hien Thi Thu; Rimpilainen, Tatu; Konda Mani, Saravanan; Murugesan, Akshaya; Yli-Harja, Olli; Candeias, Nuno R; and Kandhavelu, Meenakshisundaram, "Synthesis and preclinical validation of novel P2Y1 receptor ligands as a potent anti-prostate cancer agent." (2019). Articles, Abstracts, and Reports. 2583.